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Since the early 1950’s, considerable efforts have been expended studying the 
physico-chemical and biological properties of synthetic purine and pyrimidine bases as 
well as their corresponding nucleosides (Figure 1). Many of these studies were 
conducted because of the biological relevance of these genetically related materials. 
Eloin et al.1, in a search for purine antagonists synthesized 6-mercaptopurine (Figure 2). 
6-Mercaptopurine was one of the first drugs of this type to be used in the treatment of 
cancer. Several purine and pyrimidine analogs have been synthesized for potential drug 
use. The growing interest in pyrimidine analogs as antiviral agents is of special 
importance. For example, 3'-azido-2'-deoxythymidine (AZT) (Figure 2) is the better 
known antiviral agent, because of its use in the treatment of Acquired Immune 
Deficiency Syndrome (AIDS). Moreover, an increasing number of other purine and 
pyrimidine derivatives are being marketed for treating human viral infections. 
Iodouridine, first synthesized by W. H. Prusoff2, has been used for more than 20 years as 
an antiviral drug against the herpes virus to prevent severe ocular infections and 
blindness. A new class of noncyclic side chain derivatives of guanine has surfaced as 
potential antiviral agents against herpes viruses. 9-(2-Hydroxyethoxy-methyl)guanine 
(Acyclovir™), synthesized by H. J. Schaeffer, et.al.3, was the first in this series to be 
approved by the Federal Drug Administration (FDA) for general topical and oral use in 
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Figure 2: Modified purine and pyrimidine nucleosides. 
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Several modified nucleosides have been identified as a result of the structural elucidation 
of transfer ribonucleic acids (t-RNAs). These nucleosides, which occur as minor 
components in various t-RNAs, differ in a variety of ways from adenosine, cytidine, 
uridine, and guanosine (Figure 1). 1-Methyl and 7-methylguanosines, 1-methyl and N6- 
methyladenosines, and 2-methoxyadenosine (Figure 2) are general examples of such 
modified purines nucleosides4. More complex examples include 6-(3-methyl-2- 
butenylamino)-9-p-D-ribofuranosylpurine and N-[9-(P-D-ribofuranosyl)purin-6-yl 
carbamoyl]-L-threonine5 (Figure 2). 
Of particular interest to this investigation was the isolation of an unusual purine 
base from the phenylalanine t-RNA (t-RNAphe) of yeast6, wheatgerm7, and rat liver8. The 
fluorescent nitrogen heterocycle, designated as the "Y" base, was located adjacent to the 
3' end of the anticodon. The “Y” base attracted considerable interest because of its 
potential important biological role. It is well established that this novel structure was an 
imidazo[l,2a]purine9. Evidence for the proposed structure of the "Y" base has been 
documented by synthesis and is now known to exist in slightly different forms when 
isolated from various t-RNAs10. It is speculated that the biosynthesis of the "Y" base 
involves the reaction of guanosine with a carbon fragment from a compound such as 
glutaric acid8 (Figure 3). However, proof of such a pathway has not been documented. 
A number of studies have been undertaken to determine the role and function of the "Y" 
base in t-RNAs. Theib and Zachau7 noted that the "Y" base isolated from t-RNA of 
yeast was more labile than other modified bases. This property enabled these 
investigators to isolate a t-RNA minus the "Y" base. These authors reported that when 
the "Y" base was expelled, the t-RNA lost its ability to bind to the m-RNA: ribosomal 
RNA complex, but did not lose its amino acid accepting ability. Gosh and Gosh11 
reported that the removal of the "Y" base adjacent to the anticodon changes the coding 
properties of yeast t-RNAphe. These investigators also reported that t-RNAphe from which 
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Grunberger’s biosynthetic pathway is the only proposed pathway for “Y” base synthesis. 
Figure 3 : Proposed biosynthetic pathway of “Y” bases. 
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It is of interest to note that t-RNAphe found in hepatoma rat liver differs from the normal 
t-RNAphe of rat liver by the absence of the "Y" base12. These results provide the first 
evidence of a structural difference between a single species of t-RNA from normal cells. 
In addition, the observation that the "Y" base is compatible with a wide array of 
biological systems suggests that its analogs may be considered as a possible anti¬ 
metabolite. In fact, 5,9-dihydro-9-oxo-lH-imidazo[l,2a]purine can be viewed as a 
derivative of guanine with substitution at N-l and N-5. Retaining this basic structural 
feature of guanine is significant in that it is directly related to antiherpes activitiy13. 
Antiviral studies have revealed that the attack of effective drugs focuses on virally coded 
DNA polymerase14. For example, acyclovir is selectively phosphorylated by herpes 
coded thymidine kinase and acts as a terminator of DNA synthesis. 
Utilizing lH-imidazo[l,2a]purine, as the parent compound, analogs containing 
substitution at positions 2 and 6 have been synthesized in reasonable quantities and their 
physico-chemical and biological properties have been studied. 
Chapter 2 
Literature Review 
In 1968, U. L. Raj Bhandany and coworkers15 published an extensive review of 
the primary structure of yeast phenylalanine t-RNA (t-RNAphe). They reported the 
presence of an unidentifiable fluorescent nucleoside ("Y" nucleoside) that was located 
adjacent to the 3' end of the anticodon. R. Thiebe and H. Zachau3 isolated the purine base 
of the "Y" nucleoside by mild acid treatment of the yeast t-RNAphe. Further purification 
of the "Y" base was carried out by paper chromatography in an ethyl acetate-1-propanol- 
water (4/1/2) solvent system. Shortly thereafter, the "Y" base was isolated from t-RNAphe 
of several eukaryotic species such as wheat germ16, beef liver17, rat liver18, Torulopsis 
utilis19, and saccharamyces cervisiae20. Thiebe and Zachau noted that the removal of the 
" Y" base did not cause any major structural changes within the primary structure of t- 
RNAphe. The excision of the "Y" base did not cause any breakage within the polymeric 
chain of tRNAphe. t-RNAphe minus the "Y" base (tRNAphe y) was investigated in greater 
detail by H. Zachau3, W. Krzyzosiak21, and F. Cramer22et. al. As a result of their studies 
a comparison was made between t-RNAphe and t-RNAphe y. This study revealed that both 
t-RNAs had similar molecular sizes and shapes. However, the removal of " Y" base from 
the anticodon loop caused alterations within the anticodon and the D-loops of t-RNAphe. 
The change in conformation of the anticodon loop prevents the t-RNAphe y from binding 
to polyuridylic acid or other polynucleotides. This change results in its inability to 
transfer its amino acid onto the growing peptide chain. The "Y" base removal also 
caused thermal instability of the tertiary interactions. It was concluded from these studies 
that the "Y" base was not an essential part of the synthetase recognition region of t- 
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RNAphe, although it played a fundamental role in the structural stability and recognition of 
m-RNA codon. 
Although the first "Y" base was isolated from yeast t-RNA in 1968, its structure 
was not determined until 1970 by D. Cartwright and coworkers23. Cartwright and 
colleagues revealed the structure of the yeast "Y" base ("Yy" base) to be a- 
carboxyamino-4,9-dihydro-4,6-dimethyl-9-oxo-lH-imidazo [1,2a] purine -7-butyric acid 
dimethyl ester (Figure 4). K. Nakanishi24, A. Feinberg25, S. Matsuura23 determined the 
structure of various "Y" bases from t-RNAphe including wheat germ and mammalian liver, 
Saccharomyces cerevisiae, and Torulopsis cerevisiae respectively (Table 1). The three 
reported structures of the "Y" base that have been isolated form normal t-RNAphe include, 
a-(carboxyamino)-b-hydroxy-4,9-dihydro-4,6-dimethyl-9-oxo-lH- imidazo [1,2a] purine- 
7-butyric acid dimethyl ester (hydroxy-"Y" base; Figure 4), dimethyl-a-(carboxyamino)- 
4,9-dihydro-4,6-dimethyl-9-oxo- lH-imidazo [1,2a] purine-7-butyrate ("Yy " base and 
"Y"Sc base; Figure 4), and 4,9-dihydro-4,6-dimethyl-9-oxo-lH-imidazo[l,2a] purine 
("YXu" base; Figure 4). 
The elucidation of the structure of mammalian liver t-RNAphe enabled E. Borek26 
to identify an “under-modified” precursor of the hydroxyl-"Y" base that was specific for 
t-RNAphe of Ehrlich ascites cells. The structure was reported as a-amino-b-hydroxy-4,9- 
dihydro-4,6-dimehtyl-9-oxo-lH-imidazo [1,2a] purine-7-butyric acid (Figure 4 and 
Table 1). This hypo-modification of the hydroxyl-"Y" base was the first example of an 
extensive qualitative difference between biochemical components of normal and tumor 
and expanded the synthesis of "Y" bases. As shown in the above examples (Figures 5 
and 6), cells. The hypo-modification of the hydroxyl-"Y" base located in t-RNAphe of 
tumor cells indicated that the product from processed tumor specific t-RNAphe was not 
demonstrate that the product produced from tumor specific t-RNAphe was in fact the result 
merely the result of random scheduling of processing t-RNAphe. However, it did it 
0 






Figure 4: Proposed Structures of various “Y” bases and unmodified “Y” nucleoside 
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Table 1 
Chemical Name and Abbreviations of "Y" Bases 
Source of t-RNAphe of "Y" Base Symbol Chemical Name 
Baker's Yeast 
Saccharamycee cervisiae Yy"base &"Ysc"base 
Torulopsis utilis "YTu"base 
Mammilian Liver Hydroxy-" Y "base 
oc-carboxyamino-4,9- 
dihydroxy-4,6-dimethyl-9- 











butyric acid dimethyl ester 
The materials indicated above are not the only source of the "Y" base given. 
of modification of t-RNAphe. The identical aberrant modification of t-RNAphe in two 
different malignancies, Ehrlich ascites and Novikoff hepatoma, provided further evidence 
that the product from processed tumor specific t-RNAphe of tumor cells was the product of 
t-RNAphe modification. D. Grunberger and coworkers27, by careful observtion noted a 
difference between neuroblastoma and normal cell t-RNAphe. By using postlabeling 
techniques, Grunberger and associates determined the nucleotide sequence of the t- 
RNAphes of normal and cancer cells. Their results did not indicate any difference between 
the normal and cancer cells except for the difference in the post-transcriptional 
modification in the anticodon loop. The t-RNAphe from mouse neuroblastoma contained 
1-methyl-guanine instead of the hydroxy-" Y" base which is found in t-RNApheof normal 
neurons. Twenty five percent of the neuroblastoma t-RNAphe contained the under 
modified hydroxy-"Y" base. Grunberger and colleagues examined these conditions 
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leading to the undermodified "Y" base, and reproduced the undermodified hydroxy-"Y" 
base by methionine and lysine deprivation of Vero cells. This cell line was derived from 
African green monkey kidney, and usually contained one form of t-RNAphe that included 
the hydroxy-" Y" base. However, when methionine or lysine was removed from the 
growth medium, an additional form of t-RNAphe was observed that contained the under 
modified hydroxy-"Y" base. Grunberger and colleagues also reported the disappearance 
of the t-RNAphe yin tumor bearing mice after interperitoneal injection of amino acids and 
vitamins. It was therefore concluded that this tumor specific t-RNAphe species was the 
product of aberrant post-transcriptional modification and not the transcripts of different 
normally repressed genes. 
From the results of the starvation experiments with vero cells and the structural 
characterization of the tumor specific t-RNAphe, Grunberger proposed a hypothetical 
pathway for the "Y" base biosynthesis. It was postulated that the initial step was the 
formation of 3-methylgaunine which would act as a signal for the synthesis of the "Y" 
base. Grunberger28 had previously reported the incorporation of lysine in " Y" bases. 
Therefore, he concluded that the 2-amino group of guanine could readily react with a- 
amino adipic acid semi-aldehyde, a metabolite of lysine, to form a Schiff’s base. Closing 
the third ring and modification of the "Y" base at the appropriate position would 
complete the biosynthetic pathway. In order to explain the absence of the "Y" base in 
tumor cells, Grunberger proposed that the t-RNA methylase preferentially methylates at 
the N-l instead of the N-3 position of guanosine, causing the formation of the 1- 
methylguanosine instead of the desired 3-methylguanosine. The 3-methylguanosine 
synthesis is blocked by the formation of the 1-methylguanosine and the "Y" base 
synthesis is terminated. This proposed mechanism would provide an explanation for the 
presence of the 1-methylguanosine that is located in the neuroblastoma t-RNAphe. Before 
Grunberger postulated the biosynthetic pathway of the "Y" base, Matsuura29 and 
Nakanishi30 were developing methods to synthesize naturally occurring "Y" bases. 
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Nakanishi’s method for the synthesis of "Yy" base included the condensation of 2- 
methylcarbamoyl-5-bromo-6-oxoheptanoate with 3-methylguanine in dimethyl sulfoxide. 
Nakanishi31 later synthesized the "Ysc" base with a 20% yield by condensation of 5- 
bromo-2-carbomethoxyamine-6-oxo-heptamoate with 7-benzyl-3-methyl guanine (Figure 
5). Nakanishi also improved the synthesis of the " YTu" base that was first synthesized by 
Matsuura in 1971. He prepared the "YTu" base by a method similar to the procedure used 
for the "Ysc" base in which the 7-benzyl-3-methyl guanine undergoes condensation with 
3-bromo-2-heptanone (Figure 6).( Nakanishi improved Nakanishi synthesized the desired 
"Y" base by condensation of 7-benzyl-3-methylguanine with the appropriate a- 
, \ ?.. •• ^ iSO-fr* 
haloketone. 
In an attempt to delineate the structural features of the base moiety of acyclovir 
that were crucial to its antiviral activity, E. De Clercq, B. Golarkiewicz, and J. Boryski32 
explored the importance of the nitrogen centers of acyclovir. One or more of the nitrogen 
centers were blocked by méthylation or by the incorporation of an additional ring. The 
following "YV base derivatives (Figure 7) were used in this study: 9[(2-hydroxyethoxy) 
methyl]-1 ,N-2-isopro-penoguanine, N-2-methyl-9-[(2-hydroxyethoxy) methyl]-1 ,N-2- 
isopropenoguanine and 7-methyl-9-[(2-hydroxyethoxy) methyl]-l,N-2- 
„ -, 
isopropenoguanine. (De Clecq and colleagues reported that only 9-[(2-hydroxy- 
ethoxy )methyl]- 1 ,N-2-isopropenoguanine and 1 -methyl-9-[(2-hydroxyethoxy) 
methylguanine exhibited a marked antiherpetic activity. The activity spectra of these two 
compounds were similar to acyclovir. Their selectivity as inhibitor of herpes simplex 
virus type 1 (HSV-1) and type 2 (HSV-2), was at least as great as, if not greater than that 
of acyclovir. 9-[(2-Hydroxy-ethoxy) methyl]-l,N-2-isopropenoguanine and l-methyl-9- 
[(2-hydroxyethoxy) methylguanine were inactive against HSV-1 that was deficient in 
thymidine kinase inducing activity (TK‘ HSV-1) and varicella-zoster virus (VZV) 
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Method A is the synthesis of “Ysc” base proposed by Nakanishi in 1971 
Method B is the synthesis of “Ysc” base proposed by Nakanishi in 1978 




















Method A is the synthesis of “YTU” base proposed by Matsuura in 1971 
Method B is the synthesis of “YUJ” base proposed by Nakanishi in 1978 


















According to reports by Robins and De Clerq, all of the above derivatives had moderate to strong antiviral 
activity. 
Figure 7: N-substituted derivatives of acyclovir used in De Clercq’s viral study. 
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specific phosphorylation by the virus encoded thymidine kinase. J. Boryski, B. 
Golankiewicz, and E. De Clercq33 conducted further studies of tricyclic analogues of 
acyclonucleosides that showed strong activity against HSV-1, HSV-2, VZV, and 
cytomegalovirus. The two parent compounds used to develop derivatives of acyclovir 
and gancyclovir were 3,9-dihydro-6-methyl-9-oxo-5H-imidazo [1,2a] purine and 3,9- 
dihydro-9-oxo-5H-imidazo [1,2a] purine. 
It has been reported that several N2-substituted guanines and their nucleosides 
display selective inhibitory activity toward the HSV-1 thymidine kinase (TK) relative to 
the human enzyme "in vitro and "in vivo34 These nucleosides form non-substrate 
inhibitors of HSV1 TK in that they are resistant to phosphorylation by the virial enzyme. 
It has also been reported by E. Wright and F. Focher35 that the N2-substituted guanines 
specifically inhibit in vitro activity of guanosine phosphotransferase (GPTase). This 
enzyme is believed to be capable of synthesizing guanine nucleotides under conditions of 
imbalance between adenine and guanine nucleotides. Because of its possible role in 
purine salvage pathways, N2-substituted guanine could be considered as a possible 
antiparasitic agent. After reviewing the work of De Clercq, Boryski, and Golankiewicz, 
along with the studies conducted concerning the N2-substituted guanines, a series of 
modified 5,9-dihyro-9-oxo-lH-imidazo[l,2a] purines and their corresponding 
nucleosides were synthesized. In addition to determining the physico-chemical 
properties of these derivatives, they were also assayed for their activity against HSV-1 
Chapter 3 
Results and Discussions 
The objectives of these studies were to synthesize several modified 4,9-dihydro-9- 
oxo-lH-imidazo[l,2a]purine bases and their corresponding nucleosides, study their 
physicochemical properties, and evaluate their antiviral activity against HSV-1. These 
compounds were prepared by modifying procedures used by Nakanishi33. Nakanishi 
used one of the more popular methods for the synthesis of modified 4,9-dihydro-9-oxo- 
lH-imidazo[l,2a]purines. The alkylation of the 3-methylguaine with the appropriate 
a-haloketone was used previously by Matsurura and others21, but low yields were 
obtained. Nakanishi increased the overall reaction yields by protecting the N-7 position 
of 3-methylguanine with a benzyl group. The alkylation of guanine at position 7 
competes with position 1 as the site of alkylation. However, by protecting position N-7 
with a benzyl group, alkylation will occur primarily at position N-l. In the synthesis of 
modified 4,9-dihydro-9-oxo-lH-imidazo[l,2a]purines in this study, guanosine was 
alkylated with the appropriate a-haloketone to produce a modified 4,9-dihydro-9-oxo- 
lH-imidazo[l,2a]purine nucleoside. The nucleoside on position N-9 was used as a 
protecting group instead of the benzyl that Nakanishi used in his procedures. Guanosine 
was found to be more soluble in DMF than the 7-benzyl-3-methylguanine, and the ribose 
was a less cumbersome protecting group to remove. At 70°C, guanosine was soluble in 
DMF and remained in solution during the addition of the appropriate a-haloketone at 
25°C. 
The resulting alkylation-condensation reactions used to obtain the tricyclic bases 
and their corresponding nucleosides are shown in Reaction Schemes I and II (Figure 8 & 
17 
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9). The modified 4,9-dihydro-9-oxo-lH-imidazo[l,2a]purine bases and their 
corresponding nucleosides were synthesized in moderate yields. Elemental analysis, 
UV/Vis, Proton and C-13 NMR, and IR spectra of the desired modified 4,9-dihydro-9- 
oxo-lH-imidazo[ 1,2a] purine bases and corresponding nucleosides were consistent with 
assigned structures as discussed below. 
Analysis of the UV/Vis spectra (Table 2) data indicates substantial bathochromic 
shifts relative to starting material. These data are quite similar to those reported for the 
imidazo[l,2a]purine ribonucleoside obtained by the reaction of guanosine with 
glycidaldehyde29. 
IR Spectra 
The IR spectra of the tricylic nucleosides and bases (Table 3, Figure 10) are very 
similar in that each exhibit stretching of the carbonyl group (1700-1710 cm'1), carbon- 
nitrogen bond (1040-1100 cm'1), secondary amine (3300 cm'1), aryl carbon-hydrogen 
bond (3100 cm'1) and the aryl carbon-carbon bond (1590-1600 cm"1). The absence of 
primary amine stretching absorption at 3300-35000^ can possibly be viewed as 
evidence for the formation of the second imidazo ring. As reaction schemes I and II 
indicate, the primary amine of guanosine is included as a part of the new ring formed by 
the condensation of guanosine and the appropriate a-haloketone. The nucleosides 
exhibited absorptions associated with its nucleoside ring, including the carbon-oxygen 












Modified 5,9-Dihydro-9-Oxo-1 H-lmidazo[1.2a] 
Purine 
Figure 8: Reaction Scheme 1, synthesis of modified 5,9-dihydro-9-oxo-lH- 
imidazo[l,2]purine bases and corresponding nucleosides. 
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Table 2 








Point( °C) % Yield 
I C18H17N5O5 0.34/0.55 262 270-271 30.40 
n C18H17N505F 0.63/0.68 286 268-270 53.70 
m C19H20N5O5 0.39/0.59 260 260-263 28.60 
IV C19H20N5O6 0.37/0.55 258 255-257 26.14 
V C22H19N505 0.33/0.43 264 244-247 35.40 
VI Ci8Hi7N505Br 0.42/0.63 260 233-235 47.12 
VII C18H17N50,BrF 0.39/0.70 284 248-251 55.07 
VIII Ci9H2oN505Br 0.36/0.59 258 245-247 30.43 
IX Ci9HjoN506Br 0.44/0.64 256 260-263 37.62 
X C^HigNsOsBr 0.30/0.41 262 268-271 38.28 
XI C13H9N5O 0.50/0.66 262 257-260 82.11 
XII C13H9N50F 0.54/0.61 286 270-273 78.52 
xm C,4H12N50 0.44/0.55 260 271-274 85.35 
XIV C14H12N502 0.56/0.60 258 265-268 88.23 
XV C17H„N50 0.35/0.45 264 260-263 71.39 
XVI C13H9N5OBr 0.33/0.40 286 266-269 83.53 
XVII CnHjNsOBrF 0.34/0.15 292 260-263 89.29 
xvm C,4H12N50Br 0.46/0.55 284 266-269 86.96 
XIX CwHuNjOjBr 0.64/0.34 282 259-262 85.96 
XX CI7H„N5OBr 0.34/0.30 286 270-273 87.04 
’Developing solution A consisted of ethyl acetate, 1 -propanol, and water (4:1:2). 
developing solution B consisted of a 50:50 mixture of glacial acetic acid and acetone. 











Modified 2-Bromo-5,9-Dihydro-9-Oxo-1 H- 
lmidazoI1,2a]Purine Riboside 
H 
Modified 2-Bromo-5,9-Dihydro-9-Oxo-1 H- 
lmidazo[1,2a]Purine 
Figure 9: Reaction Scheme 2, Synthesis of modified 2-bromo-5,9-dihydro-9-oxo-lH- 
imidazo[l,2a]purine bases and corresponding nucleosides. 
22 
Table 3 
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I 1700 1040 — 3400 3150 1590 980 3300 
n 1710 1090 3150 3100 1600 990 3300 
in 1750 1050 3180 — 3150 1580 960 3300 
IV 1725 1060 3200 — 3100 1620 980 3300 
V 1700 1100 3225 — 3110 1550 980 3300 
VI 1705 1045 3200 — 3150 1520 960 3300 
vn 1695 1060 3180 — 3100 1600 980 3300 
vm 1739 1095 3250 — 3200 1610 1000 3300 
IX 1700 1040 3200 — 3100 1590 980 3300 
X 1780 1050 3150 3100 1580 960 3300 
XI 1702 1040 3225 — 3150 1550 — — 
XII 1750 1080 3250 — 3100 1600 — — 
xra 1700 1050 3200 — 3150 1580 — — 
XIV 1710 1100 3210 — 3150 1605 — — 
XV 1750 1050 3260 3120 1610 — — 
XVI 1700 1040 3210 3150 1560 — — 
XVII 1710 1100 3250 — 3100 1600 — 
XVIII 1725 1050 3200 — 3100 1620 — — 
XIX 1700 1040 3250 — 3150 1580 — — 















The 6-phenyl derivatives of the imadazo[l,2a] purines and imadazo[l,2a] purine 
ribosides (compounds I-XX) exhibited absorption related to the phenyl ring and the 
imidazo[l,2a] purines (Table 4 & Figure 11). The absorption associated with the phenyl 
ring varied in each phenyl derivative. The absorption related to phenyl ring of 6-phenyl- 
9-oxo-3-(P-D-ribofuranosyl)-7-H-imidazo[1.2a]purine, and compounds I, VI, XI, and 
XVII shows a doublet of triplets at 7.4 ppm that represents three hydrogens, and doublet 
at 7.9 ppm that represents two hydrogens. Compounds II, VU, XII, and XVII have a 
fluorine at the fourth position of the phenyl ring which produces a doublet at 7.4 ppm and 
doublet at 8.2 ppm, both representing two hydrogens. 
In compounds IE, VIII, XIII, and XVIII there is substitution at position 4 with a 
methyl group which gives a doublets at 7.4 and 7.8 ppm that integrate to two hydrogens. 
For compounds IV, EX, XIV, and XIX, there is substitution at position 2 of the phenyl 
ring that result in a triplet at 7.0 ppm (1H), a doublet at 7.2 ppm (1H), triplet at 7.5 ppm 
1H), and a doublet at 8.0 ppm (1H). Compounds V, X, XV, and XX each has a naphthyl 
group at position 6 which results in a multiplet at 8.0 ppm (5H), a doublet at 8.3 ppm 
(1H), and a singlet at 8.5 ppm (1H). The absorption related to the imidazo[l,2a] purine 
ring is observed as a singlet at 8.0 ppm (2H) only when no substitution is present at 
position C-2. However, for the 2-bromo derivatives of the imidazo[l,2a] purines the 
singlet at 8.0 ppm only represent one hydrogen. A singlet at 6.1 ppm (1H) corresponds 
to the hydrogen at position N-5. 
Portions of the proton NMR of the tricyclic ribosides I-X resemble the proton 
spectra of guanosine, and 8-bromoguanosine. Compounds I-X, guanosine and 8- 
bromoguanosine contain a nucleoside sugar which show characteristic absorption of a 
series of singlets and doublets between 3.5-5.8 ppm (Table 4). The proton spectra of the 
tricyclic purine bases are similar to the nucleus of the corresponding riboside analogues. 
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Table 4 
Proton NMR of Modified Purines and Corresponding Nucleosides 
Com¬ 
pound 
H2 H4 H7 Aromatic 
ring 
NH2 NH 
Guanosine 8.0 (s) 6.1 (s) 8.0 (s) — 6.5w 10.71 (b) 
i 8.0 (s) 6.1 (s) 8.0 (s) 7.4 (dt), 7.9 (d) — — 
n 8.0 (s) 6.1 (s) 8.0 (s) 7.4(d), 8.2(d) — — 
m 8.0 (s) 6.1 (s) 8.0 (s) 7.4(d), 7.8(d) — — 
rv 8.0 (s) 6.1 (s) 8.0 (s) 7.0(t),7.2(d),7.5(t) — — 
V 8.0 (s) 6.1 (s) 8.0 (s) 8.0 (m), 8.3(d), 8.5(s) — — 
VI — 6.1 (s) 8.0 (s) 7.4 (dt), 7.9 (d) — — 
VII — 6.1 (s) 8.0 (s) 7.4(d), 8.2(d) -- — 
vni — 6.1 (s) 8.0 (s) 7.4(d), 7.8(d) — — 
IX — 6.1 (s) 8.0 (s) 7.0(t),7.2(d),7.5(t) -- — 
X — 6.1 (s) 8.0 (s) 8.0 (m), 8.3 (d), 8.5(s) -- — 
XI 7.45 (s) 6.1 (s) 8.0 (s) 7.4 (dt), 7.9(d) — — 
XII 7.45 (s) 6.1 (s) 8.0 (s) 7.4(d), 8.2(d) ... — 
xm 7.45 (s) 6.1 (s) 8.0 (s) 7.4 (d), 7.8 (d) — — 
XIV 7.45 (s) 6.1 (s) 8.0 (s) 7.0 (t), 7.2(d). 7.5(t) — — 
XV 7.45 (s) 6.1 (s) 8.0 (s) 8.0(m),8.3 (d), 8.5 (s) — — 
XVI 6.1 (s) 8.0 (s) 7.4 (dt), 7.9 (d) ... — 
XVII — 6.1 (s) 8.0 (s) 7.4(d), 8.2(d) — 
XVIII — 6.1 (s) 8.0 (s) 7.4(d), 7.8(d) — — 
XLX — 6.1 (s) 8.0 (s) 7.0 (t), 7.2(d), 7.5(t) — — 
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Figure 11 NMR spectra of compound I 
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C-13NMR 
C-13 NMR and C-13 DEPT (at a 135° pulse) were performed on compounds I- 
XX (Tables 5-7, Figures 12 & 13). The chemical shifts observed for a compound in C-13 
DEPT experiments will be identical to chemical shifts observed in C-13 NMR. 
According to Martha Burch, Cecil Dybowski, and Robert Lichter36 C-13 DEPT 
experiments at a 135° pulse, will produce a positive signal for methine and methyl groups 
and a negativesignal for methylene groups. C-13 experiments at a 45° pulse will observe 
methyl, methylene, and methine as positive signal, while a 90° pulse will only give 
methine carbon signals. The presence of a methylene or a methyl group would indicate 
that the product was the schiff s base and not the Y base. By conducting C-13 DEPT 
experiments at 135° pulse one experiment can be used for the detection of the presence of 
both methyl and methlene. 
The C-13 spectras of these compounds are very similar with only minor 
differences. The most common peaks for each spectra were peaks associated with the 
imidazo[l,2a] purine ring, which are in agreement with spectra reported by R. K. 
Robins37. These common peaks include, 104 ppm (C-7), 116 ppm (C-6), 138 ppm (C-2), 
147 ppm (C- 10), 150 ppm (C-9), and 151 ppm (C-8). Compounds I-XX also contain a 
phenyl ring that varies in spectra according to the type of substitution present. All 
chemical shifts associated with the phenyl ring were in agreement with spectra as 
reported by Robert Silverstein, G. Clayton Brasser and Terence C. Morrill38. In 
compounds I, VI, XI, and XVI there is a unsubstituted phenyl ring that produces peaks at 
137.15 ppm (C-l"), 129.03 ppm (C-2"), 128.67 ppm (C-3"), and 125.08 ppm (C-4"). 
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Table 5 
Chemical Shifts of Guanosine for Proton and C-13 NMR 














!C-5 produces a negative absorption within C-13 depth experiments at a 90 degree pusle. 
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Table 6 
C-13 NMR Spectra Associated with the Purine Ring of the 





























I 137 129 128 125 128 129 — — — — 
n 137 129 128 125 128 129 — — — — — 
in 137 129 128 125 128 129 — — — — 16 
IV 137 128 130 127 121 112 — — — — 50 
V 136 130 130 129 128 128 127 126 128 123 — 
VI 137 129 128 125 128 129 — — — — — 
vn 137 129 128 125 128 129 — — — — — 
vm 137 129 128 125 128 129 — — — — 16 
IX 137 128 130 127 121 112 — — — — 50 
X 136 130 130 129 128 128 127 126 124 123 — 
XI 137 129 128 125 128 129 — — — — — 
xn 137 129 128 125 128 129 — — — — — 
XIII 137 129 128 125 128 129 — — — — NK-) 
XIV 137 128 130 127 121 112 — — — — 
5®() 
XV 136 130 130 129 128 128 127 126 124 123 — 
XVI 137 129 128 125 128 129 — — — — — 
XVII 137 129 128 125 128 129 — — — — — 
xvm 137 129 128 125 128 129 — — — — 16 
XIX 137 128 130 127 121 112 — — — — 50 
XX 136 130 130 129 128 128 127 126 124 123 — 
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Table 7 
C-13 Spectra Associated with Phenyl and Naphtyl Rings of the 





























I 137 129 128 12S 128 129 — — — — 
n 137 129 128 125 128 129 — — — — — 
in 137 129 128 125 128 129 — — — — 16 
IV 137 128 130 127 121 112 — — — — 50 
V 136 130 130 129 128 128 127 126 128 123 — 
VI 137 129 128 125 128 129 — — — — 
vn 137 129 128 125 128 129 — — — — — 
vm 137 129 128 125 128 129 — — — — 16 
IX 137 128 130 127 121 112 — — — — 50 
X 136 130 130 129 128 128 127 126 124 123 —- 
XI 137 129 128 125 128 129 — — — — — 
xn 137 129 128 125 128 129 — — — — — 
xm 137 129 128 125 128 129 — — — — UK-) 
XIV 137 128 130 127 121 112 — — — — 
5*B 
XV 136 130 130 129 128 128 127 126 124 123 —- 
XVI 137 129 128 125 128 129 — — — — — 
XVII 137 129 128 125 128 129 — — — — — 
xvni 137 129 128 125 128 129 — — — — 16 
XIX 137 128 130 127 121 112 — — — — 50 
XX 136 130 130 129 128 128 127 126 124 123 — 
ru o in 
m CD N 
ai 
en T ID r\j — o 
m v to 'v in 01 
O — CD 1X5 LO CD 
\îï \W 
in en un "V 
en en 
11 
eu rs. co 
n *» in u N œ en 
so in ■» n a, « 
MB n « o> s n 

























 at a 135 D
egree Pulse of com
pound I. 
I 0 h . il v 
12'). ?.. a 
i 2 !.. . y i 
11!).'! 9 








8 b • 9 2 
7 4.78 







Compounds II, III, VII, VIII, XII, XIII, XVII, and XVIII contain a fluoro or a 
methyl group (16 ppm) at position 4 of the phenyl ring. These substitutions result in an 
insignificant change in the chemical shift of the phenyl ring (Table 7). The methoxy 
group (50 ppm) when substituted at position 2 of the phenyl ring in compounds IV, IX, 
XIV, and XIX results in the following peaks: 112 ppm (C-6'), 121 ppm (C-51), 127 ppm 
(C-4')> 128 ppm (C-2'), 130 ppm (C-3') and 137 ppm (C-T). Compounds V, X, XV, and 
XX posess a naphthyl group at position 6 resulted in peaks at 123 ppm (C-10'), 124 ppm 
(C-9'), 126 ppm (C-8'X 127.7 ppm (C-7), 128 ppm (C-6' and C-5'), 129.5 ppm (C-4'), 130 
ppm (C-3'), 130 ppm (C-2'), and 135.5 ppm (C-T). Compounds I- X exhibited a series of 
additional peaks that were attributed to the nucleoside moiety (Table 6), which include 
the following chemical shifts: Cf at 74.78 ppm, C2' at 88.01 ppm, C3' at 85.92 ppm, C4' 
at 71.03 ppm and C5' at 62.03 ppm. The chemical shifts for Cf, C2', C3', and C4' are 
observed as a positive signals at a 135° pulse in C-13 DEPT experiments. However, C5' 
is observed as a negative signal. The negative signal for C5' can be attributed to the 
mehtylene group at this position. 
i 
Cytotoxicity Studies 
The cytoxicity studies (Table 8) showed that the purine ribosides without 
substitution at position 2, were the least toxic compounds of this series. These 
compounds showed no significant cytotoxicity toward the cells at a concentration of 50 - 
100 pg/ml. However, 2-bromo-6-(4'-fluorophenyl)-9-oxo-3-(P-D-ribofuranosyl)-7-H- 
imidazo[ 1 2a]purine, and 2-bromo-6-naphthyl-9-oxo-3-(P-D-ribofuranosyl)-7-H- 
imidazo[l 2a]purine were the most toxic. No cytotoxic effects on the cells were observed 
at a concentration of 12.5 pg/ml. The remaining compounds exhibited similar cytotoxic 
effects at the same concentration. All compounds examined exhibited significant 
cytotoxcity toward the cells at concentrations greater than 200 pg/ml, while at 
concentration lower than 12.5 pg/ml no evidence of cell death was present. 
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Viral Assay 
The viral assays of compounds I-XX ( Table 8) showed inhibition with all twenty 
compounds at a concentration of 6.25|Jg/ml, and the majority of the compounds showed 
some inhibition even at 3.12 (Jg/ml. On the other hand, compounds IV, VIII, XIV, XV, 
XVII, and XIX exhibited evidence of increased viral activity. The most effective 
compounds in this series were compounds I, II, and III. These compounds showed 
considerable antiviral activity (> 50% inhibition) at concentration of 6.25and 3.12 |ig/ml. 
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Table 8 
Results of Toxicity Studies and Viral Assays 
Compounds 
|dg/ml4 HSV1 (|ig/ml)5 
I 100 6.25 
n 50 3.12 
m 100 6.25 
IV 100 25 
V 25 25 
VI 25 25 
VII 25 25 
vm 25 25 
IX 25 25 
X 100 25 
XI 100 25 
XII 25 25 
xm 25 25 
XIV 25 25 
XV 25 25 
XVI 100 25 
xvn 25 25 
xvm 25 25 
XIX 25 25 
XX 25 25 
4The concentration of the compound at which no significant cytotoxic effects were noticed.. 
sThe lowest concentration at which the viral activity is decreased by 50% or lower.. 
Chapter 4 
Conclusions ) 
If a-haloketone does not form the desired tricyclic riboside with guanosine or 8- 
bromoguanosine it could possibly cause alkylation at positions N-l or the nitrogen on 
C-2. These alkylated products would produce a negative signal for C-13 DEPT 
experiments corresponding to a methylene group. However, it was reported by 
Townsend and Robins40 that alkylation at position 7 or 9 mono-substituted guanine under 
basic conditions occurs predominantly at position 1. .Which would eliminate the '' 
possibility of alkylation occurring at N-2. 41 The absence of infrared absorption, 
associated with a primary amine in the infrared spectra of compounds I-XX, is an 
indication that substitution occurred on the nitrogen at position C-2 of guanosine or 8- 
bromoguanosine. Proton NMR spectra of these compounds did not show the presence of 
absorption that corresponded to a primary amine between 1-5 ppm. The absence of a 
primary amine supports the assumption that a third ring had been formed. The C-13 
DEPT spectra at a 135° pulse gave one negative signal at 62.1 ppm for purine ribosides 
and no negative signals for purine bases. The negative signal found in the purine 
ribosides can be attributed to the presence of the methylene group in the ribose moiety. 
Based on spectral data and the findings of Townsend and Robins, it can therefore be 
concluded that the second imidazo ring was formed. 
Based on the current results, it may be concluded that the 2-bromo derivatives of 
the modified 4,9-dihydro-9-oxo-lH-imidazo[l,2a]purine bases and their corresponding 
nucleosides are not potent antiviral agents, nor are the modified 4,9-dihydro-9-oxo-lH- 
imidazo[l,2a]purines. However, it was surprising to note that the corresponding 
36 
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ribosides showed more pronounced antiviral activity than their bases. In contrast, Broski 
and others reported that ribosides were less toxic to the cells and produced lower 
antiherpetic activity than their bases. Compounds I, H, and III were less toxic to the cells, 
but were more potent than their bases. Although compounds I, H, and HI exhibited 
antiherpetic activity, at low concentrations, their concentrations were approximately 100 
fold higher than the concentration observed for acyclovir. These compounds showed 
antiviral activity at concentrations of 100 fold lower than the tricyclic ribosides that had 
been previously reported. Compounds I, H, and III were not as active as acyclovir, but 1- 
(2-acetoxyethoxy)methyl and 1 -(2-Hydroxyethoxy)methyl derivatives of compounds I, 
II, and II show great promise as antiviral agents. Reports by Robins and De Clerq have 
shown, novel N-substituted derivatives of ganciclovir and acyclovir, l-(2-acetoxy- 
ethoxy)methyl and l-(2-Hydroxyethoxy)methyl derivatives of guanosine, show an 
increase in antiviral activity when compared to their bases and nucleosides. 
Future studies of these modified “Y” bases and nucleosides should include the 
synthesis and characterization of both their l-(2-acetoxyethoxy)methyl and l-(2- 
Hydroxyethoxy)methyl derivatives. It is anticipated that a 50-100 fold increase in the 
antiviral activity and a slight increase in cytotoxicity, would be observed if the above 
derivatives are synthesized and assayed. 
References 
1. G. B. Elion, E. Burgi and G. H. Hitchings. Journal of American Chemical 
Society. 74.411.(19521. 
2. W. H. Prusoff, Biophvsic Acta. 32, 295, (1959). 
3. L. M. Beauchamp, B. L. Dolmatch, H. J. Shaeffer, P. Collins, D. J. Baueer, P. M. 
Kelleer, and J. A. Fyfe, Journal Medicinal Chemistry. 28, 982, (1984). 
4. J. D. Smith and D. B. Dunn, Biochemistry Journal. 72, 294, (1959). 
5. G. B. Cheda, R. H. Hall, D. I. Magarth, J. Mozeiko, M. P. Schweizer, L. Stasiuk, 
and P. R. Taylor, Biochemistry. 8, 3278, (1960). 
6. R. Theib and H. G. Zachau, European Journal of Biochemistry. 5, 546, (1960). 
7. B. S. Dudock, G. Katz, E. D. Taylor, and R. W. Holley, Procedure National 
Academy Science USA. 57,751, (1960). 
8. L. M. Fink, T. Goto, F. Frankel, and J. B. Weinstein, Journal of American 
Chemical Society. 32,7617, (1970). 
9. K. Nakanishi, N. Furrtachi, D. Grunberger, and J. B. Weinstein, Journal of the 
American Chemical Society. 32,7617, (1970). 
10. H. Kasai, M. Goto, K. Ikeda, M. Zama, Y. Mizuno, S. Takemura, S. Matsuura, T. 
Sugimoto, and T. Goto, Biochemistry Journal. 79, 642, (1958). 
11. K. Ghosh and H. P. Ghoush, Journal of Biological Chemistry. 247, 3369, (1972). 
12. I. Gruenberger, B. Winstein, and J. F. Mushinski. Nature. 253, 66, (1975). 
13. L. Beachamp, B. L. Dolmatch, H. J. Shaefer, P. Collins, D. J. Bauer, A. Fyfe, 
Journal of Medicinal Chemistry. 28,982, (1985). 
14. M. J. Robins, P. W. Hatfield, J. Balzarini, E. DeClerq. Journal Medicinal 
Chemistry. 27,1486 (1984). 
38 
39 
15. U. L. RajBhandry, R. D. Fualkner, and Alexander Stuart, Journal of Biological 
Chemistry. 243, 575 (1968). 
16. D. S. Dudock, G. Katz, R. W. Holey, Fed. Proc. Fed. Am. Soc. Exp. Biol., 27, 
342 (1968). 
17. D. Yoshikami, G. Katz, amd D. S. Dudouck. Biochem, Biophvs. Acta, 166, 714 
(1968). 
18. L.M. Fink, and T. Goto, Biochem. Biophvs. Res. Comm.. 32, 963 (1968). 
19. L. M. Fink, L. W. Lanks, T. Got, and S. Matsuura, Tetrahedron Lett., 2725 
(1971). 
20. U. L. RajBhandary, A. Stuart, R. D. Faulkner, Cold Spring Harbor Svmo. Ouan. 
BioL, 31,425 (1966) 
21. W. J. Krzyzosiak and Ciesiolka, Nucleic Acid Research. 11, 6913 (1983). 
22. N. Okabe and F. Cramer, J. Biochem.. 89,1439 (1981). 
23. D. Cartwright, R. A. Gardiner, and K. L. Rinehart. J. Am. Chem. Soc.. 92, 7617, 
(1970). 
24. K. Nakanishi, S. Blobstein, and G. Grunberger, Nature. 234, 107 (1971). 
25. A. M. Feinberg, K. Nakanishi, and M. Wiewiorowski, J. Am. Chem. Soc.. 96, 
7797 (1974). 
26. Y. Kuchino and E. Borek, Nature. 271, 126, (1978). 
27. D. Grunberger, R. G. Pergolizzi, Y. Kuchino, and S. Nishimura, Recent Results in 
Cancer Research. 84, 133 (1983). 
28. R. Pergolizzi, D. Engelhard!, D. Grunberger, Nucleic Acid Research. 6, 2209, 
(1979). 
29. L. M. Fink, L. W. Lanks, T. Goto, and S. Matsuura, Tetrahedron Lett.. 2725 
(1971). 
30. A. M. Feinberg, K. Nakanisi, and M. Wiewioroski, J. Am. Chem. Soc.. 96,7797, 
(1974). 
31. C. R. Frihart, A. M. Feinbergt, K. Nakanishi, J. Organic Chem.. 43,1644 (1978). 
32. J. Boryski, B. Golankiewicz, and E. DeClercq, J. Med. Chem.. 34, 2380 (1991). 
33. J. Boryski, B. Golankiewicz, and E. DeClercq, J. Med. Chem.. 31, 1351 (1988). 
40 
34. F. Foucher, C. Hidebran, and S. Freese, and N. Spadari, J. Med. Chem.. 31,1496 
(1988). 
35. F. Foucher, C. Hidebran, and S. Freese, and N. Spadari, J. Med. Chem.. 33, 203. 
(1990). 
36. Robert Lichter and Cecil Dybowski, NMR Spectroscopy Techniques. Marcel 
Dekker, Inc., New York 234 (1980). 
37. R. K. Robins, Proceedings of the National Academy of Science. 65,27, (1970). 
38 Robert M. Silverstien, G. Clayton Basser, and Terrence Morrill, Spectrometric 
Identification of Organic Compounds. John Wiley and Son, New York, (1974). 
39. L. B. Townsend and R. K. Robins, J. Am. Chem. Soc.. 84, 3008 (1962). 
